CA2241462A1 - Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer - Google Patents

Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer Download PDF

Info

Publication number
CA2241462A1
CA2241462A1 CA002241462A CA2241462A CA2241462A1 CA 2241462 A1 CA2241462 A1 CA 2241462A1 CA 002241462 A CA002241462 A CA 002241462A CA 2241462 A CA2241462 A CA 2241462A CA 2241462 A1 CA2241462 A1 CA 2241462A1
Authority
CA
Canada
Prior art keywords
breast cancer
enantiomer
treatment
pharmaceutically acceptable
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002241462A
Other languages
English (en)
French (fr)
Inventor
Michael Shalmi
Ved Prakash Kamboj
Omkar Prasad Asthana
Suprabhat Ray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2241462A1 publication Critical patent/CA2241462A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002241462A 1996-01-11 1997-01-09 Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer Abandoned CA2241462A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1000096P 1996-01-11 1996-01-11
US60/010,000 1996-01-11
DK77696 1996-07-11
DK0776/96 1996-07-11

Publications (1)

Publication Number Publication Date
CA2241462A1 true CA2241462A1 (en) 1997-07-17

Family

ID=26064631

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002241462A Abandoned CA2241462A1 (en) 1996-01-11 1997-01-09 Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer

Country Status (12)

Country Link
EP (1) EP0873119A1 (hu)
JP (1) JP2001500101A (hu)
KR (1) KR19990077157A (hu)
AU (1) AU1367197A (hu)
BR (1) BR9706966A (hu)
CA (1) CA2241462A1 (hu)
CZ (1) CZ217198A3 (hu)
HU (1) HUP9901633A3 (hu)
IL (1) IL124881A0 (hu)
NO (1) NO983177L (hu)
PL (1) PL328135A1 (hu)
WO (1) WO1997025034A1 (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1143899A (en) * 1997-11-10 1999-05-31 Novo Nordisk A/S Transdermal delivery of 3,4-diarylchromans
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
AU2004200099B2 (en) * 1998-06-11 2006-11-02 Endorecherche, Inc. Medical Uses of A Selective Estrogen Receptor Modulator in Combination with Sex Steroid Precursors
AU2011253842B2 (en) * 1998-06-11 2014-08-14 Endorecherche Inc. Medical Uses of a Selective Estrogen Receptor Modulator in Combination with Sex Steroid Precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
WO2006042409A1 (en) 2004-10-20 2006-04-27 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
CN102940619A (zh) 2007-10-16 2013-02-27 利普生物药剂公司 用于治疗代谢综合征的珠氯米芬
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
CA2802761C (en) 2010-06-16 2017-01-03 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
CA2865234A1 (en) 2012-02-29 2013-09-06 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
CN108348605B (zh) 2015-11-10 2023-06-09 帕拉卡林治疗公司 用pdgf-cc抑制剂和抗雌激素治疗er阴性乳癌

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447622A (en) * 1981-09-22 1984-05-08 Council Of Scientific And Industrial Research Rafi Marg Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof

Also Published As

Publication number Publication date
BR9706966A (pt) 1999-05-04
PL328135A1 (en) 1999-01-18
AU1367197A (en) 1997-08-01
HUP9901633A3 (en) 2000-02-28
EP0873119A1 (en) 1998-10-28
KR19990077157A (ko) 1999-10-25
IL124881A0 (en) 1999-01-26
JP2001500101A (ja) 2001-01-09
CZ217198A3 (cs) 1998-11-11
WO1997025034A1 (en) 1997-07-17
NO983177L (no) 1998-07-10
HUP9901633A2 (hu) 1999-10-28

Similar Documents

Publication Publication Date Title
CA2241462A1 (en) Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
US5726202A (en) Benign prostatic hypertrophy
US5883118A (en) Prostatic carcinoma
KR19990077156A (ko) 폐경기 증상의 치료 또는 예방을 위한 약학적 조성물의제조를 위한 3,4-디페닐크로만의 사용
JPH10511962A (ja) 婦人科疾患の治療または予防用の医薬組成物の製造への３，４−ジフェニルクロマンの使用
NZ504656A (en) Substituted aminomethyl-chromans are used for the regenerative treatment of neurological conditions which are the sequelae of damage due to surgical intervention, exposure to toxic agents, infections, tumours, and other diseases and conditions
AU701411B2 (en) Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis
US5756539A (en) 3, 4-diphenyl chromans for inhibiting one or more psychiatric disorders
EP0804189A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis or for anticoagulative treatment
US5886021A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis
US5780502A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
WO1998033499A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for increasing libido in post-menopausal women
WO1998033500A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting senescence-associated motor impairment
WO1998032437A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more psychiatric disorders
JPH10511960A (ja) 特発性の又は生理学的な女性化乳房の治療又は予防のための医薬製剤の製造のための３，４−ジフェニル・クロマンの使用
WO1998002154A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
EP0973519A1 (en) Inclusion complexes in aqueous solution
CN1207037A (zh) 西替考马l－对映体在制备治疗或预防乳癌药物组合物中的应用
CN1207038A (zh) 3,4－二苯基苯并二氢吡喃在生产预防或治疗绝经症状的药物组合物中的应用
MXPA97005379A (en) Use of the 3,4-difenil-chromians for the manufacture of a pharmaceutical composition for treatment or profilaxis vasodilatad
MXPA97005214A (en) Use of the 3,4-difenil-chromanos for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia or arterioesclerosis or for anti-treatment
WO1998034608A1 (en) Methods for treatment or prophylaxis of menopausal symptoms

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20020109